ArticleResearch and practice in thrombosis and haemostasis2026
Visualization of new vessel formation during venous thrombus organization using genetic fate mapping.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial cell (EC) dysfunction contributes to venous thrombosis, and disrupting endothelial angiogenic signaling delays venous thrombus resolution. However, the time course of EC appearance during venous thrombus organization and the identity of cells lining the intrathrombotic vessels are largely unknown. Objectives: We used a genetic fate mapping approach to visualize tamoxifen-inducible endothelial receptor tyrosine kinase (TIE2) reporter ECs during venous thrombus resolution and human pulmonary thrombi of different organizational stages to validate our findings. Methods: We induced stenosis and deep vein thrombosis by ligating the inferior vena cava in mice expressing membrane targeted green fluorescent protein in postembryonic TIE2 lineage cells. TIE2 reporter ECs started to appear on day 7 and lined the newly formed vessel-like structures within thrombi on day 21. Results: Immunolabeling identified endomucin as most specific marker of angiogenic ECs in venous thrombi. Intercellular adhesion molecule 2, a marker of EC activation, was expressed predominantly on ECs lining the adjacent aorta, not the inferior vena cava. Cells expressing the hypoxia surrogate marker carboanhydrase IX, stromal cell-derived factor 1 alpha, or CD34 peaked on day 7, whereas endothelial protein C receptor-expressing cells appeared later. Platelet-derived growth factor beta lineage-derived pericytes and fibrosis were detected from day 14 onwards. Histologic analysis of thrombus material from patients with acute pulmonary embolism or chronic thromboembolic pulmonary hypertension confirmed the presence of endomucin-, CD34-, and endothelial protein C receptor-positive cells in organized pulmonary thrombus material, whereas vessel-like structures were only seen in chronic thromboembolic pulmonary hypertension thrombi. Conclusion: TIE2 reporter ECs appear in venous thrombi early and prior to measurable reductions in thrombus size, whereas pericytes appear later and possibly contribute to vessel stabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.